Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Merck
McKesson
Baxter

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Pictilisib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Pictilisib?

Pictilisib is an investigational drug.

There have been 6 clinical trials for Pictilisib. The most recent clinical trial was a Phase 2 trial, which was initiated on January 20th 2012.

The most common disease conditions in clinical trials are Breast Neoplasms, Glioblastoma, and Lung Neoplasms. The leading clinical trial sponsors are Genentech, Inc., Roche Pharma AG, and Royal Marsden NHS Foundation Trust.

There are five hundred and eighty-two US patents protecting this investigational drug and six international patents.

Recent Clinical Trials for Pictilisib
TitleSponsorPhase
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibInstitute of Cancer Research, United KingdomPhase 1
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibPfizerPhase 1
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibRoche Pharma AGPhase 1

See all Pictilisib clinical trials

Clinical Trial Summary for Pictilisib

Top disease conditions for Pictilisib
Top clinical trial sponsors for Pictilisib

See all Pictilisib clinical trials

US Patents for Pictilisib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pictilisib ⤷  Try it Free Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try it Free
Pictilisib ⤷  Try it Free Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) ⤷  Try it Free
Pictilisib ⤷  Try it Free In vitro production of foregut stem cells Cambridge Enterprise Limited (GB) ⤷  Try it Free
Pictilisib ⤷  Try it Free Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pictilisib

Drugname Country Document Number Estimated Expiration Related US Patent
Pictilisib Australia AU2015231053 2034-03-21 ⤷  Try it Free
Pictilisib Brazil BR112016021620 2034-03-21 ⤷  Try it Free
Pictilisib Canada CA2943339 2034-03-21 ⤷  Try it Free
Pictilisib China CN106231900 2034-03-21 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Merck
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.